Quest Diagnostics Incorporated (DGX)vsNatera Inc (NTRA)
DGX
Quest Diagnostics Incorporated
$233.72
+0.76%
HEALTHCARE · Cap: $25.72B
NTRA
Natera Inc
$275.19
+1.79%
HEALTHCARE · Cap: $38.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Quest Diagnostics Incorporated generates 362% more annual revenue ($11.56B vs $2.50B). DGX leads profitability with a 9.2% profit margin vs -9.1%. DGX earns a higher WallStSmart Score of 60/100 (C).
DGX
Buy60
out of 100
Grade: C
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
0.0% earnings growth
Weak financial health signals
Trading at 22.1x book value
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DGX
Revenue growth of 10.2% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : DGX
The primary concerns for DGX are PEG Ratio.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
DGX profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.50 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
DGX generates stronger free cash flow (330M), providing more financial flexibility.
Bottom Line
DGX scores higher overall (60/100 vs 31/100) and 10.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Quest Diagnostics Incorporated
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?